In comparison, AFP showed much lower sensitivity in early stage of HCC in both BCLC and TNM staging system (BCLC 0 and A: 50.5% (45.9–55.1%); TNM I: 44.7% (40.3–49.2%)). The gene discussed is AFP; the disease is hepatocellular carcinoma.